We Are Providing Diagnostic &
Therapeutic Solutions
Sapphire Biotech’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived oncological therapeutics.
COVID-19 TESTING
CLINICAL therapeutics
Sapphire’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market
Dedicated to Changing Lives Through Research
Sapphire Biotech has identified a unique enzyme, Quiescin Sulfhydryl Oxidase 1 (QSOX1), which is elevated in cancer patients and can be detected earlier than circulating tumor cells. The company’s development of QSOX1 as a unique cancer biomarker has led it to important discoveries based on testing hundreds of human samples. Sapphire’s lead compound has been tested in animal studies has shown to significantly reduce tumors by two-thirds in under 20 days.
Global Demand and Growing Market Potential
With the oversight and expertise of internationally-recognized scientists and medical experts, Sapphire Biotech not only has great potential to help hundreds of millions of cancer patients throughout the U.S., but also become a strategic asset for its investors. The global cancer therapy market is experiencing a strong growth pattern with a CAGR over the next four years of 8.37% and 90% of cancer patients dying from metastatic cancer. Sapphire’s team has developed never-before-seen and proven compounds to combat metastatic cancer.
$136.2 Billion
2018 Global Cancer Therapy Market Value
$220.7 Billion
Estimated Global Cancer Therapy Market Value by 2024
90%
Of cancer deaths are caused by metastatic cancer
Biotech Professionals Express Fears…and Hope, During Pandemic
The fourth-most mentioned fear (at 14%) was a resurgence or a spike in infections after restrictions are lifted. Much about the SARS-CoV-2 virus is still being discovered. “Our biggest fear regarding the pandemic is that there will be future waves of outbreaks until...
Clinical Trial Begins Using Sapphire Biotech’s Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer
Sapphire Biotech scientists have developed a new lateral flow assay test to measure the enzyme QSOX1 that is found to be elevated in subjects with pancreatic cancers. The purpose of the trial is to evaluate the diagnostic potential of Sapphire’s lateral flow assay to...
Sapphire Biotech Files for Small Business Investigational Research Grant to Develop Compounds That Target Metastasis
Sapphire Biotech has filed for a Small Business Investigational Research (SBIR) grant to develop potent and soluble analogs of SBI-183, a compound that has been shown to inhibit tumor growth and metastasis. The SBIR would fund Sapphire’s scientists’ ongoing research...
Reach Us
Sapphire Biotech, Inc.
6191 Cornerstone Court, E., Suite 114
San Diego, CA 92121
info@sapphirebiotech.com